New Strong Sell Stocks for June 23rd
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
SG Americas Securities LLC Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH
Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low – Here’s Why
Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.00 Consensus Target Price from Analysts
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.00 Consensus Price Target from Analysts
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
Amphastar Director Sells 16,679 Shares for $441,800
Amphastar Announces FDA Approval for Teriparatide Injection
Capital Fund Management S.A. Takes $931,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Down 15.4% in 4 Weeks, Here's Why Amphastar (AMPH) Looks Ripe for a Turnaround